The therapeutic targeting of anaplastic lymphoma kinase (ALK) has been a burgeoning area of research since 2007 when ALK fusions were initially identified in patients with non-small cell lung cancer. The field has rapidly progressed through development of the firstgeneration ALK inhibitor, crizotinib, to an understanding of mechanisms of acquired resistance to crizotinib and is currently witnessing an explosion in the development of next-generation ALK inhibitors such as ceritinib, alectinib, PF-06463922, AP26113, X-396, and TSR-011. As with most targeted therapies, acquired resistance appears to be an inevitable outcome. Current preclinical and clinical studies are focused on the development of rational therapeutic strategies, including novel ALK inhibitors, as well as rational combination therapies to maximize disease control by delaying or overcoming acquired therapeutic resistance. This review summarizes the existing clinical data and ongoing research pertaining to the clinical application of ALK inhibitors in patients with non-small cell lung cancer.
Interestingly, aside from NSCLC, many other tumor typesin both pediatric and adult malignancies-have been shown to harbor oncogenic ALK abnormalities. These include ALK amplification and ALK point mutations in patients with neuroblastoma, ALK point mutations in patients with anaplastic thyroid carcinoma, and ALK gene fusions in patients with anaplastic large cell lymphoma, diffuse large B cell lymphoma, inflammatory myofibroblastic tumor, and others. 9 For the specific details of known ALK point mutations and fusions, we refer the reader to a recently published review. 7 
INITIAL THERAPEUTIC TARGETING
The therapeutic efficacy of ALK inhibition in patients with ALK-rearranged NSCLC was first demonstrated with crizotinib (PF-02341066) in the PROFILE series of clinical trials (Table 1) . Crizotinib is an oral inhibitor of the tyrosine kinases ALK, mesenchymal-epithelial transition (MET) factor, and c-ros oncogene 1 (ROS1). 7 In a phase I clinical trial, crizotinib demonstrated a 60.8% objective response rate (ORR), a median progressionfree survival (PFS) of 9.7 months, and overall survival (OS) rates of 87.9% at 6 months and 74.8% at 1 year in patients with advanced ALK-rearranged NSCLC. 10 In this clinical trial, ALK rearrangements were identified with fluorescence in situ hybridization, and the frequencies of specific ALK fusion gene types were not reported. 10 In a retrospective analysis using this phase I data comparing OS between 30 patients with ALK-rearranged NSCLC treated with crizotinib in the second-or third-line setting to 23 patients with ALK-rearranged NSCLC treated with standard, non-ALK inhibitor therapy in the second-line setting, patients who received crizotinib had a significantly longer 2-year OS, 55% versus 12% (P = 0.004). 25 The phase II clinical trial assessing crizotinib in patients with ALK-rearranged NSCLC who had undergone at least 1 prior line of therapy showed a similar ORR of 60% and a PFS of 8.1 months.
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In a subsequent phase III, open-label clinical trial involving 347 patients with locally advanced or metastatic ALK-rearranged NSCLC who had received 1 line of prior therapy with a platinumbased regimen, patients treated with crizotinib compared with standard cytotoxic chemotherapy (pemetrexed or docetaxel) had significantly better ORR and PFS, but no demonstrable OS benefit. In this clinical trial, the ORR was 65% in the crizotinib arm compared with 20% in the control arm (P < 0.001), median PFS was 7.7 months in the crizotinib arm compared with 3.0 months in the control arm (P < 0.001), and median OS was 20.3 months in the crizotinib arm compared with 22.8 months in the control arm (P = 0.54). Importantly, the OS data were calculated on an intention-to-treat basis, and 64% of patients randomized to conventional chemotherapy in the second-line setting went on to receive crizotinib. The frequencies of specific ALK fusion gene types were not reported in this clinical trial. 12 Similar results were obtained when crizotinib was compared with conventional cytotoxic chemotherapy with pemetrexed and either cisplatin or carboplatin in a phase III clinical trial involving 343 patients with treatment-naive, ALK-rearranged, advanced NSCLC. In this cohort, the ORR was 74% in patients treated with crizotinib compared with 45% in patients treated with cytotoxic chemotherapy (P < 0.001), and the median PFS was 10.9 months in patients treated with crizotinib compared with 7.0 months in patients treated with cytotoxic chemotherapy (P < 0.001). One-year OS was not statistically different, as it was 84% in patients receiving crizotinib and 79% in patients receiving cytotoxic chemotherapy. Similar to the aforementioned second-line phase III clinical trial, this first-line therapy trial was assessed on an intention-to-treat basis, 70% of patients randomized to first-line cytotoxic chemotherapy eventually received crizotinib, and the frequencies of specific ALK fusion gene types were not reported. 13 The time from the initial discovery of ALK alterations in patients with NSCLC to Food and Drug Administration approval of crizotinib for the treatment of patients with ALK-rearranged NSCLC was 4 years. The impressive example of ALK-rearranged NSCLC serves as a paradigm for accelerated approval of molecularly targeted therapies in cancer care.
MECHANISMS OF ACQUIRED RESISTANCE
As occurs among patients with epidermal growth factor receptor (EGFR)-mutant NSCLC treated with EGFR tyrosine kinase inhibitors (TKIs), patients with ALK-rearranged NSCLC have been shown to acquire resistance to ALK inhibition with crizotinib by several mechanisms, broadly classified as target modification and "bypass" signaling ( Fig. 2) . Target modifications include ALK gene amplification, present in approximately 9% of tumors resistant to crizotinib, 26 as well as point mutations and insertion mutations in the tyrosine kinase domain of the EML4-ALK fusion protein, 7, 27 which have been observed in approximately one third of patients with crizotinib-resistant tumors. 26 Unlike the EGFR T790M "gatekeeper" mutation, which is the predominant point mutation detected in approximately 50% to 60% of patients with acquired resistance to first-and secondgeneration EGFR TKIs, crizotinib resistance mutations appear to span the ALK kinase domain. The analogous gatekeeper mutation, L1196M, has been detected. Other mutations include L1152R, C1156Y, I1171T/N/S, F1174L/C/V, V1180L, G1202R, S1206Y, and G1269A. The clinical frequency of the various ALK kinase domain mutations that confer crizotinib resistance is actively being studied. In addition to modification of the ALK target, bypass pathway signaling has also been shown to mediate crizotinib resistance in several preclinical and clinical studies. This bypass signaling serves to provide an escape mechanism for the tumors to functionally circumvent the inhibited ALK fusion protein and signal to progrowth downstream pathways through redundant FIGURE 1. Schematic representation of the EML4-ALK fusion protein. The EML4-ALK fusion is formed via an abnormal rearrangement on chromosome 2, which juxtaposes part of the N-terminus of EML4 to a portion of the C-terminus of ALK. The N-terminus of EML4 contains a coiled-coiled domain, which mediates EML4-ALK dimerization. Dimerization has been shown to be critical for EML4-ALK activity. The ALK portion of the fusion contains the entire ALK tyrosine kinase domain. EML4-ALK is the most common ALK fusion described in lung cancer to date; however, other ALK fusion partner have also been described. EML4-ALK fusion proteins are clients of the HSP-90 chaperone, and they signal downstream through the mitogen-activated protein kinase (MAPK) pathway, the phosphatidyl-inositol-3-kinase-AKT pathway, and the JAK-STAT pathway to mediate pleiotropic progrowth and prosurvival effects. 29 and Src 30 have also been detected at the time of crizotinib resistance. Finally, genomic amplification of cKIT has been detected in patients at the time of crizotinib resistance. 28 A second concern related to a potential therapeutic ceiling with crizotinib treatment for ALK-rearranged NSCLC is its central nervous system (CNS) penetration. While it has been noted that crizotinib's cerebrospinal fluid concentration is low compared with plasma (0.26% that of the plasma crizotinib concentration), 31 the brain parenchymal concentrations of crizotinib are unknown. It has also been observed that in patients with ALK-rearranged NSCLC treated with crizotinib intracranial metastases are a common site of disease progression. However, it is not clear whether this represents primary or acquired resistance to crizotinib because the mechanisms underlying CNS progression in patients treated with crizotinib are unknown. 32 Targeting the CNS as a sanctuary site in patients with ALK-rearranged NSCLC is a key aspect of therapy with second-generation ALK inhibitors, and comparisons of the efficacy of these newer agents with crizotinib for CNS disease are ongoing.
THERAPEUTIC STRATEGIES TO OVERCOME ACQUIRED RESISTANCE
Multiple second-generation ALK inhibitors are currently in clinical trials, both in the setting of patients with acquired resistance to crizotinib and as first-line therapies.
Ceritinib (LDK378) is a second-generation oral ALK inhibitor, which has shown efficacy when used to treat patients with locally advanced or metastatic ALK-rearranged NSCLC, including those whose tumors have acquired resistance to crizotinib. In a phase I clinical trial, among 114 patients with ALK-rearranged NSCLC who received at least 400 milligrams of ceritinib daily, the ORR was 58%, and the PFS was 7.0 months. Among 86 patients who had previously been treated with crizotinib, the ORR remained 56%, indicating that ceritinib therapy was able to overcome acquired resistance to crizotinib in a substantial proportion of patients. Specifically, among 7 patients in whom crizotinib resistance via ALK point mutations in the tyrosine kinase domain or ALK gene amplification was identified before treatment with ceritinib, 6 (86%) experienced an objective response.
14 In preliminary results from 2 larger clinical trials (ASCEND 2 and ASCEND 3; NCT01685060 and NCT01685138, respectively), among 140 patients previously treated with platinum-based chemotherapy who had progressed through crizotinib, the ORR was 54%, and the PFS was 5.7 months. 15 In 124 patients with ALKrearranged NSCLC who were ALK inhibitor naive, the ORR was 79%, and the PFS was 11.1 months. 16 Alectinib (CH5424802/RO5424802) is a second-generation oral ALK inhibitor that has also shown efficacy in patients with ALK-rearranged NSCLC. In a phase I clinical trial involving 44 patients with ALK-rearranged NSCLC who developed resistance to crizotinib or were intolerant of crizotinib, the ORR was 55%. 17 In a phase I/II clinical trial of alectinib in 46 patients with ALK-rearranged, advanced NSCLC with no prior ALK inhibitor therapy, the ORR was 93.5%, and the PFS is expected to be greater than 29 months. 18, 19 Furthermore, there has been suggestion that alectinib may have improved therapeutic efficacy for CNS metastases compared with crizotinib and ceritinib, as it achieves notably higher cerebrospinal fluid levels and has induced CNS disease responses in tumors resistant to crizotinib and ceritinib. [33] [34] [35] Two additional phase II clinical trials have shown an ORR of 48% to 49% in patients with ALK-rearranged, locally advanced or metastatic NSCLC who had progressed through crizotinib (NCT01801111 and NP28761). 20, 21 PF-06463922 is an oral inhibitor of ALK and ROS1 that has been shown to have antitumor effects in both ALK-rearranged and ROS1-rearranged preclinical models. 36 PF-06463922 is currently in a phase I/II clinical trial, preliminary results of this trial have been reported. Among 18 patients with ALK or ROS1-rearranged advanced NSCLC, the ORR was 40%, and 5 of the 6 patients with documented responses to PF-06463922 had progressed through prior ALK TKI therapy (NCT01970865). 37 FIGURE 2. Mechanisms of resistance to crizotinib and second-generation ALK inhibitors both share common strategies and exploit novel routes. Specific ALK tyrosine kinase point mutations have been identified as imparting only resistance to crizotinib (L1196M) or enabling resistance to both crizotinib and second-generation ALK inhibitors (G1202R). Similarly, specific bypass signaling pathways have been identified in conjunction with resistance to crizotinib (IGF-1R), resistance to second-generation ALK inhibitors (MET factor), or resistance to both crizotinib and second-generation ALK inhibitors (EGFR).
Brigatinib (AP26113) is an oral ALK inhibitor currently in a phase I/II clinical trial. At the most recent interval reporting of this trial 79 patients with advanced, ALK-rearranged NSCLC had been treated with an ORR of 72% and median PFS of 14 months (NCT01449461). 22 X-396 is an oral ALK inhibitor also currently in a phase I/II clinical trial. At the most recent interval reporting of this trial in 2014, among 17 patients with ALK-rearranged NSCLC, the ORR was 59%, and the ORR among the 13 patients previously treated with crizotinib was 54% (NCT01625234). 23 TSR-011 is an oral ALK and tropomyosin receptor kinase inhibitor that is being evaluated in patients with ALK-rearranged tumors, including NSCLC, in a phase I trial. Data from this trial have shown an optimal dose regimen of 120 mg/d, and 3 of 3 patients have achieved an objective response. 24 
RESISTANCE TO SECOND-GENERATION AGENTS
Resistance to second-generation ALK inhibitors is an active area of investigation. Mechanisms of resistance to crizotinib and second-generation ALK inhibitors show overlap as well as novel mechanisms outlined in Figure 2 . Similar to crizotinib resistance mechanisms but with less well-defined frequencies, resistance to second-generation ALK inhibitors has been observed to occur through ALK point mutations and alternative signaling pathways including EGFR, Src, MAP2K1, MEK, and MET factor activation.
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SEQUENTIAL ALK INHIBITION AND COMBINATION STRATEGIES
One of the most pressing questions facing the application of ALK inhibitors in patients with ALK-rearranged NSCLC is the optimal sequential or combination therapy regimen to utilize in order to maximize disease control and survival. In an early assessment of sequential ALK inhibitor therapy, a retrospective analysis has shown that among patients treated sequentially with crizotinib followed by ceritinib after progression on crizotinib the median combined PFS is 17.4 months and OS is 49.4 months. 35 In this analysis, there was no difference in PFS with ceritinib therapy based on the presence or absence of a known crizotinib resistance-mediating ALK mutation. 35 Prospective trials evaluating the sequence of investigational ALK TKIs versus crizotinib are being planned.
To maximize disease control and patient survival, heterogeneous resistance mechanisms, such as the simultaneous existence of ALK point mutations and alternative pathway activation, must be addressed. Acknowledging the need to simultaneously inhibit multiple oncogenic checkpoints in the same patient, several combination strategies including vertical pathway inhibition, horizontal pathway inhibition, HSP-90 inhibition, ALK inhibition combined with immunotherapy, and ALK inhibition combined with cytotoxic chemotherapy have been proposed. Vertical pathway inhibition refers to inhibiting multiple components within the same oncogenic pathway, such as combined MEK and ALK inhibition. Horizontal inhibition, in contrast, refers to inhibiting multiple different oncogenic pathways simultaneously, such as combining ALK inhibition with Src, IGF-1R, EGFR, or cKIT inhibition.
The combination of ALK inhibition with immunotherapy is an active area of investigation, stimulated in part by an analogous finding that EGFR-mutant NSCLC utilizes activation of the programmed cell death 1 and programmed cell death ligand 1 pathway to evade destruction by a patient's immune system. 40 This treatment strategy is being assessed through a phase I clinical trial of combination ceritinib and the programmed cell death 1 inhibitor nivolumab (NCT02393625).
Finally, based on data suggesting that patients with ALKrearranged NSCLC are sensitive to pemetrexed-based cytotoxic chemotherapy, 41 there is an ongoing clinical trial comparing the combination of pemetrexed and crizotinib to pemetrexed alone in patients with ALK-rearranged NSCLC that has progressed through crizotinib monotherapy (NCT02134912).
CONCLUSIONS
ALK fusions in lung cancer serve as the paradigm for the rapid and successful translation of a new biomarker from initial discovery to full clinical integration and widespread use of ALKdirected targeted therapies for patients whose tumors harbor this alteration. There are several important questions to pursue moving forward in this field: (1) With the ongoing clinical development of several new ALK TKIs, how can we systematically study and define the optimal sequence of ALK-directed therapies in this cohort of patients? (2) All of the studies to date have examined the efficacy of ALK TKIs in patients with metastatic disease. Will ALK TKIs be efficacious in the adjuvant setting? This question is being addressed in the ALCHEMIST-ALK clinical trial, which will assess the efficacy of crizotinib versus placebo in patients with ALK-rearranged lung cancer following standard-of-care adjuvant therapy. 42 (3) Will the specific ALK gene fusion dictate clinical responses? At present, ALK fusions are detected primarily by fluorescence in situ hybridization, which detects only an ALK gene rearrangement and cannot detect the actual fusion variant. However, as next-generation sequencing-based technologies move to the forefront of clinical diagnostics, the field will be able to assess how the various different ALK fusion partners and fusion variants effect responses. (4) Finally, as the field of ALK inhibition in patients with NSCLC advances, there is a pressing need to determine the generalizability of findings in NSCLC to other tumor types where ALK point mutations, amplification, and rearrangements have been identified. As an example, crizotinib has shown clinical activity in patients with ALK-rearranged anaplastic large cell lymphoma and inflammatory myofibroblastic tumors and in a minority of patients with neuroblastoma. 43, 44 To address this question, 1 arm of the National Cancer Institute Molecular Analysis for Therapy Choice Program is testing crizotinib in patients with ALK-rearranged malignancies besides NSCLC. 
